The ongoing search for better and safer treatments for multiple myeloma, a type of blood cancer, has taken a significant step forward with the development of a new cell therapy by Arcellx and Gilead Sciences. The pioneering approach demonstrated a substantial reduction or total eradication of
Naobios and Sumagen Canada Inc., a subsidiary of CreoSG Co., Ltd, have achieved a critical milestone in the development of Sumagen’s HIV-1 vaccine candidate, SAV001. This genetically modified, whole-killed HIV vaccine has shown both tolerance and safety in phase I trials, marking a significant step
In a significant move, Compass Pathways has announced its decision to lay off 30% of its workforce, streamline its research efforts, and explore selling its digital technologies. This decision comes in response to delays in the development of its lead drug, a synthetic form of psilocybin aimed at
Jade Biosciences, a burgeoning developer specializing in immune disease drugs, has set its sights on accelerating its market presence through a reverse merger with Aerovate Therapeutics. This strategic consolidation will enable Jade to promptly enter the public market under the Nasdaq ticker
Neurogene, a trailblazer in the gene therapy field concentrating on rare neurological diseases, has successfully clinched $200 million through a private funding deal designed to extend its financial runway until late 2027. This financing structure, recognized as a PIPE financing (Private Investment
Roche is considering seeking accelerated approval for its experimental Alzheimer’s drug, trontinemab, following promising early results. Trontinemab is currently in Phase 2 testing and has shown significant potential in reducing amyloid levels in the brain. This approach has been previously
